The Indian government has approved imports of Moderna’s SARS-COV-2 vaccine, to be handled by Cipla, as it seeks to tackle the pandemic via both imports and retention of domestically produced vaccines. Cipla’s supply chain activity has already been increasing with Indian imports linked to the firm up by 10.0% in April versus Q1’21 on a daily average basis. That included a 114.2% rise in active pharmaceutical ingredients (APIs). Total Indian imports of APIs climbed 21.0% over the same period, led by Cipla alongside increases in shipments linked to Cadila and Sun Pharma of 110.0% and 71.6% ...